visu’l
Directions
By public transportation
From Bahnhof Basel SBB take Tram 1 (direction Dreirosenbrücke)
in front of the main station to the stop Novartis Campus.
From Basel Badischer Bahnhof take either Tram 6 (direction
Allschwil) or Tram 2 (direction Binningen) to the stop Messeplatz.
Change to Tram 14 (direction Dreirosenbrücke) to the stop
Novartis Campus.
By car
Motorway A2 direction Basel, exit at Basel Nord/Kleinhünigen/
St Johann/Mulhouse/France, enter the tunnel and follow the
signs to Basel St. Johann and then to Novartis Main entrance and
Parking. The first basement of Novartis parking is exclusively
Maulbeerstrasse 66
CH-4058 Basel
reserved for visitors.
T +41 61 697 66 51
F +41 61 697 39 76
More information
www.fmi.ch
Friedrich Miescher Institute for Biomedical Research
Sandra Ziegler HandschinNicole Jascur
+41 61 696 15 39
+41 61 697 72 55
[email protected]
[email protected]
Part of the Novartis Research Foundation
From Basic Research to
Pharmaceutical Breakthrough
Program March 16, 2010
13.00–18.00 | Gehry Building, Novartis, Basel
13.00Welcome
Prof. Paul Herrling, Head of Corporate Research, Novartis
Opening words
Dr. Christoph Eymann, Regierungsrat Basel-Stadt
13.15Shaping the future: The FMI in 2010
Prof. Susan M. Gasser, Director, Friedrich Miescher
Institute for Biomedical Research
13.20A new academia-industry partnership for
the info-nano-bio convergence?
40 years Friedrich Miescher Institute for Biomedical Research
40 years at the interface of academia and industry
This year the Friedrich Miescher Institute for Biomedical
The FMI Anniversary Celebration, which takes place on the
Research of the Novartis Research Foundation will celebrate
Novartis campus, presents a series of presentations
its 40th anniversary. The FMI will be celebrating 40 years
by high-profile speakers, who will explore the optimal framework
of excellent biomedical research, 40 years of sustained commit-
for successful integration of fundamental research into
ment to the training of the next generation of scientists
pharmaceutical development.
and – last but not least – 40 years of translating the fruits of
Throughout its 40 years of existence, the FMI has successfully
basic research into biomedical application.
helped translate basic biomedical findings for the drug
Prof. Patrick Aebischer, President, EPFL
14.00 Restoring vision: From mice to men
discovery process. From research at the frontiers of understanding, to the elaboration of new methods and technologies,
Dr. Botond Roska, Junior Group Leader, FMI
14.20mTOR: a validated target for the treatment
of human cancer
Dr. Heidi Lane, Head of Cancer Biology, Basilea
14.40Clinical development of everolimus in oncology:
Afinitor is born
Dr. Michel Maira, Senior Research Investigator I, NIBR
15.00Changing the grammar of drug discovery
FMI scientists have helped the development of drugs like
Prof. Mark C. Fishman, President, Novartis Institutes for
Gleevec and Afinitor.
BioMedical Research (NIBR)
Insight, innovation and novel approaches are the gifts that
basic research institutes like the FMI have to offer to
those in industry who seek to put biomedical understanding
to work for the benefit of patients.
Coffee break
16.20Regulation of genes by epigenetic repression
Dr. Dirk Schübeler, Senior Group Leader, FMI
16.40Understanding complexes that safeguard the genome
Dr. Nicolas Thomä, Junior Group Leader, FMI
Please register for the event on the FMI anniversary website
Part of the Novartis Research Foundation
www.fmi.ch/anniversary/
17.00How discovery research works and why it matters
Sir Paul M. Nurse, President, Rockefeller University
17:40Reception